MACS® GMP PepTivator® SARS-CoV-2 Select

The MACS GMP PepTivator® SARS-CoV-2 Select is a peptide pool that consists of 88 lyophilized peptides of 9–22 aa in length. 63 of these peptides are MHC class I and 25 peptides are MHC class II–restricted. The peptides originate from structural proteins (S, M, N, E) as well as non-structural proteins.

The peptides are restricted for the following HLA-molecules: HLA-A*01, A*02, A*03, A*11, A*24, A*29, A*30, A*31, A*68, B*07, B*08, B*15, B*27, B*35, B*40, B*44, B*54, B*58, C*07, DRB1*01, DRB1*03, DRB1*04, DRB1*07, DRB1*11, DRB1*15.

It has been developed for efficient

... read more

Related products for MACS® GMP PepTivator® SARS-CoV-2 Select

Specifications for MACS® GMP PepTivator® SARS-CoV-2 Select
Overview

The MACS GMP PepTivator® SARS-CoV-2 Select is a peptide pool that consists of 88 lyophilized peptides of 9–22 aa in length. 63 of these peptides are MHC class I and 25 peptides are MHC class II–restricted. The peptides originate from structural proteins (S, M, N, E) as well as non-structural proteins.

The peptides are restricted for the following HLA-molecules: HLA-A*01, A*02, A*03, A*11, A*24, A*29, A*30, A*31, A*68, B*07, B*08, B*15, B*27, B*35, B*40, B*44, B*54, B*58, C*07, DRB1*01, DRB1*03, DRB1*04, DRB1*07, DRB1*11, DRB1*15.

It has been developed for efficient in vitro stimulation and subsequent isolation of SARS-CoV-2–specific CD4+ and CD8+ T cells.

Detailed product information
Background information

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), also known as novel coronavirus 2019-nCoV, causes fever, severe respiratory illness, and can lead to life-threatening pneumonia. The first cases of this disease, termed COVID-19 for coronavirus disease 2019, have been detected in December 2019 in Wuhan, China.

Applications

The MACS GMP PepTivator® SARS-CoV-2 Select can be used for a variety of applications, for example, in vitro stimulation of SARS-CoV-2-specific CD4+ and CD8+ T cells for the enrichment of IFN-gamma–secreting T cells using the CliniMACS® Cytokine Capture System (IFN-gamma) (# 279-01).3

Quality statement

MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

Disclaimer

MACS GMP Products are for ex vivo cell processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.

Resources for MACS® GMP PepTivator® SARS-CoV-2 Select
Certificates

Enter the lot number from your product label to access its Product Quality Certificated (PQC).

Get certificate

Citations for MACS® GMP PepTivator® SARS-CoV-2 Select
Publications
  1. Chu, Y. et al. (2021) Manufacture and Immunological Characterization of GMP-Compliant Functional Sars-COV-2 Cytotoxic T Lymphocytes (CTLs) Utilizing the Clinimacs® Cytokine Capture System. Blood 138: doi.org/10.1182/blood-2021-145620
  2. Thieme, C. J. et al. (2020) Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with Recovery in Critical COVID-19 Patients. Cell Rep Med. 1 (6): 100092

You have previously chosen International as your location.
What do you want to do?